ATHX
$1.81
Athersys
($.10)
(5.00%)
ATHX
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.03)
Revenue:  $0.00 Mil
Monday
Feb 8
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ATHX reports earnings?
Beat
Meet
Miss

Where is ATHX's stock price going from here?
Up
Flat
Down
Stock chart of ATHX
Analysts
Summary of analysts' recommendations for ATHX
Score
Grade
Pivots
Resistance
$2.03
$1.97
$1.94

$1.88

Support
$1.84
$1.78
$1.75
Tweet
Growth
Description
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an off the shelf allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly